Global pharmaceutical compliance standards have been tightened in 2026, and drug regulatory authorities in multiple countries reiterate that distillation is the preferred process for producing Water for Injection (WFI). Both Chinese Pharmacopoeia and European Pharmacopoeia EP define multi-effect distillers as the official water production solution for sterile preparations and vaccines, different from reverse osmosis composite processes permitted in some regions. Industry surveys show that 62% of domestic pharmaceutical factories directly adopt 3–8 effect multi-effect distillers during production line expansion. Distillation can completely remove endotoxins, microorganisms, heavy metals and organic impurities, with stable effluent endotoxin below 0.25EU/mL, fully complying with online TOC and conductivity monitoring standards of USP<643> and USP<645>.
Low-cost non-standard equipment on the market carries hidden risks. Small workshops use ordinary stainless steel and simplified heat exchange structures, which easily cause water quality fluctuations, leading to rectification notices during overseas audits of many pharmaceutical enterprises. Qualified manufacturers adopt mirror-polished sanitary 316L stainless steel, dead-leg-free pipelines and PLC remote data traceability systems, providing complete DQ/IQ/OQ/PQ validation documents. Driven by expanding biopharmaceutical capacity, orders of energy-saving MVR mechanical vapor recompression distillers rise by 27% year-on-year. Lower steam consumption greatly cuts long-term operation costs for drug manufacturers. The export volume of compliant domestic distillation equipment keeps growing in Southeast Asia, the Middle East and Russia, making it a mainstream choice for overseas pharmaceutical plant renovation, with increasing inquiries from global pharmaceutical engineering contractors.
